(Reuters) - Ariad Pharmaceuticals Inc stopped the most advanced trial of ponatinib (Iclusig) after some patients developed blood clots in their arteries.
Seven other trials of ponatinib will continue after the halt of the late-stage trial for patients with newly diagnosed chronic myeloid leukemia (CML).
The US Food and Drug Administration recently placed a partial hold on new enrollments for all trials testing the drug.
The company said today it had come to an agreement with the FDA that the trial in newly diagnosed CML should be terminated.
The FDA said last week it was investigating a number of reports of serious and life-threatening adverse events in patients taking the drug.
Ponatinib was approved by the FDA in December to treat relapsed or refractory chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, but the label warned of the potential for blood clots and liver toxicity.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου